Corvus Pharmaceuticals Inc - fluxo de caixa trimestral (NASDAQ:CRVS)

Financials

Cash from operating activities -8.46 M-8.26 M-5.78 M-9.57 M-9.19 M -32.8 M Cash from investing activities -6.08 M4.24 M-20.3 M-2.62 M10.88 M -7.8 M Cash from financing activities 18.61 M279 K35.77 M360 K20 K 36.43 M Free cash flow -8.46 M-8.3 M-5.89 M-9.57 M-9.22 M -32.97 M

Notícias

Corvus Pharmaceuticals Stock: Strong Clinical Narrative, Already Priced For Success (CRVS)

Cantor Fitzgerald reitera classificação das ações da Corvus Pharmaceuticals

Cantor Fitzgerald reiterates Corvus Pharmaceuticals stock rating

Oppenheimer raises Corvus Pharmaceuticals stock price target to $33

Corvus Pharmaceuticals, Inc. (CRVS) Q4 2025 Earnings Call Transcript

Corvus Pharmaceuticals sobe com dados de ensaio clínico em dermatite atópica

Corvus Pharmaceuticals rises on atopic dermatitis trial data

Corvus Pharmaceuticals divulga resultados após dados positivos de ensaio clínico

Corvus Pharmaceuticals earnings on deck after positive trial data

Resultados da Corvus em foco: entusiasmo com pipeline justifica alta das ações?

Corvus earnings up next: Can pipeline buzz justify stock surge?

Corvus Pharmaceuticals, Inc. (CRVS) Discusses Phase 1 Clinical Trial Results of Soquelitinib in Atopic Dermatitis with Focus on Cohort 4 - Slideshow (NASDAQ:CRVS) 2026-01-27